Assessment of Nogo-66 Receptor 1 Function In Vivo After Spinal Cord Injury. Issue 1 (3rd March 2014)

• Record Type: Journal Article
• Authors: Tong, Jing; Ren, Yi; Wang, Xiaowei; Dimopoulos, Vassilios G.; Kesler, Henry N.; Liu, Weimin; He, Xiaosheng; Nedergaard, Maiken; Huang, Jason H.
• Is Part Of: Neurosurgery. Volume 75:Issue 1(2014)
• Page Start: 51
• Page End: 60
• Publication Date: 2014-03-03
• Subjects: Animal studies -- Axonal regeneration -- Nogo receptors -- Spinal cord injury; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1227/NEU.0000000000000337
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: BACKGROUND: Neuronal Nogo-66 receptor 1 (NgR1) has attracted attention as a converging point for mediating the effects of myelin-associate inhibitory ligands in the central nervous system, establishing the growth-restrictive environment, and limiting axon regeneration after traumatic injury. OBJECTIVE: To investigate the factors that may be contributing to the discrepancy in the importance of NgR1, which has been undermined by several studies that have shown the lack of substantial axon regeneration after spinal cord injury (SCI) in NgR1-knockout or -knockdown animal models. METHODS: We used mice carrying either a homozygous or heterozygous null mutation in the NgR1 gene and subjected them to either a moderate or severe SCI. RESULTS: Locomotor function assessments revealed that the level of functional recovery is affected by the degree of injury suffered. NgR1 ablation enhanced local collateral sprouting in the mutant mice. Reactive astrocytes and chondroitin sulfate proteoglycans (CSPGs) are upregulated surrounding the injury site. Matrix metalloproteinase-9, which has been shown to degrade CSPGs, was significantly upregulated in the homozygous mutant mice compared with the heterozygous or wild-type mice. However, CSPG levels remained higher in the homozygous compared with the heterozygous mice, suggesting that CSPG-degrading activity of matrix metalloproteinase-9 may require the presence of NgR1. CONCLUSION: Genetic ablation of NgR1 may lead to significant recovery in locomotor function after SCI. The difference in locomotor recovery we observed between the groups that suffered various degrees of injury suggests that injury severity may be a confounding factor in functional recovery after SCI.